中文The biopharmaceutical pipeline is expanding rapidly, and with it the demand for efficient lyophilization, or freeze-drying, processes that stabilize everything from proteins and attenuated viruses to antibody drug conjugates (ADCs) and mRNA lipid nanoparticles (LNPs). Conventional batch freeze-drying has long been the standard, but it is slow, sometimes taking days, and carries known risks: product quality issues from limited freezing speeds, broken vials, difficulty running operator-free, and costly revalidation when scaling up. A new continuous spin-freeze-drying technology is changing that equation, and it could reshape how high-value medicines are manufactured at scale.
RheaVita, a Belgium-based specialist, offers the RheaLyo, a commercially available, GMP-ready continuous freeze-drying solution for biologics. According to Joe Brendle, director of business development and sales for North America, the process is fundamentally different from batch methods. “It’s a spin-freezing and then freeze-drying technology. So, it’s minutes to freeze versus hours normally with batch freeze-drying, and then hours versus days with a normal batch freeze-drying,” he explains. The spinning motion creates a thin ice layer on the vial walls, dramatically increasing surface area so the product freezes and dries far faster than the cake that forms at the bottom of a stationary vial, where geometry works against speed and uniformity in ways operators have long tolerated.
Major pharmaceutical companies appear convinced. In 2025, Sanofi presented its experience using RheaVita’s RheaLyo in combination with DIANT jet technology for continuous nanoparticle production, improving cycle time and stability for an mRNA LNP product. Pfizer has shared experimental work with spin freeze-drying of LNP, adeno-associated virus and protein formulations. At a 2023 conference, GSK cited a reduction in freeze-drying time from 47 hours with traditional batch processing to just three hours with continuous spin freeze-drying, a more than tenfold improvement that would have been unthinkable a decade ago and one with direct implications for pandemic responsiveness and supply resilience when every hour of capacity counts.
The technology is primarily aimed at biologics, higher-value, medium-batch products, and it is especially advantageous for newer modalities such as LNP-based RNA vaccines, where lipid nanoparticles typically must be frozen faster to preserve structure. For GMP production, RheaVita uses isolator technology that removes human operators from the process, aligning with updated Annex 1 guidelines that impose stricter requirements for sterile medicinal product manufacturing. “Human beings are the largest source of contamination,” Brendle notes, explaining that robotics and isolators help maintain sterility throughout and reduce the risk of batch failure that can cost millions and delay therapies for patients who need them without warning.
RheaVita’s system handles 16 vials at a time, freezing them and moving them into smaller clean-in-place and sterilization-in-place chambers for a few hours before stoppering. It uses standard tubing vials but does not require a lyo or split stopper. Critically, the company has seen none of the vial breakage common in batch freeze-drying, because the cylindrical ice formed by spin freezing directs forces differently than the cake at the bottom of a vial. An open vial is gently handled by a robotic arm for stoppering, further reducing breakage risk and protecting both product and operator from glass hazards that plague conventional lines and inflate rejection rates.
Process analytical technology (PAT) is built in. Contactless temperature measurement gives feedback throughout the entire drying cycle, something impossible in a batch freeze dryer where edge effects cause uneven drying across shelves. Near-infrared spectroscopy and thermal imaging provide in-line information about residual moisture, protein conformation and solid state, giving manufacturers confidence that every vial meets specifications rather than relying on end-of-run sampling that may miss a bad batch and expose patients to risk they never agreed to accept.
The financial case is compelling. Alain Segers, chief commercial officer, describes it as a “premium technology” with slightly higher capital expenditure than a batch freeze dryer but significant long-term savings. RheaVita’s modular approach can save three to nine months from R&D to commercial scale, and the ability to “scale out” rather than “scale up” eliminates the costly revalidation that batch systems require. Manufacturers can save millions from shorter development time and reduced waste alone, a powerful argument as pipelines grow more complex and time-to-market decides revenue in a fiercely competitive sector where weeks of delay can mean lost exclusivity.
With the global lipid nanoparticle market projected to grow from $786.4 million in 2024 to $1,541.6 million by 2030, and rising demand for ADC freeze-drying, RheaVita is positioned for strong growth. As Segers puts it, these high-value, modest-capacity modalities are exactly the company’s sweet spot, making the technology “really future-proof.” For packaging and device engineers, the vial-handling and stoppering advances are a reminder that the container is as much a part of the process as the drug inside, and that the next leap in biopharma may come as much from how we dry as from what we formulate at the molecular level under the microscope.
